Management of patients with newly diagnosed chronic myeloid leukemia: Opportunities and challenges

Elias Jabbour; Jorge Cortes; Susan O'Brien; Mary Beth Rios; Francis Giles; Hagop Kantarjian

doi:10.3816/CLM.2007.s.002

Management of patients with newly diagnosed chronic myeloid leukemia: Opportunities and challenges

Elias Jabbour, Jorge Cortes, Susan O'Brien, Mary Beth Rios, Francis Giles, Hagop Kantarjian^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome. This arises from a balanced translocation between chromosomes 9 and 22, creating the bcr-abl fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation, which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy. After imatinib treatment, > 90% of patients had a complete hematologic response, and 70%-80% had a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging and exhibit a major change in the natural history of the disease. The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance. The outlook today for patients with CML is much brighter than that of a few years ago.

Original language	English (US)
Pages (from-to)	S51-S57
Journal	Clinical Lymphoma and Myeloma
Volume	7
Issue number	SUPPL. 2
DOIs	https://doi.org/10.3816/CLM.2007.s.002
State	Published - Mar 2007

Funding

Dr Jabbour is a member of the Speaker’s Bureau for Novartis Oncology and Bristol-Myers Squibb. Dr Cortes has received research support from Breakthrough Therapeutics, Novartis Oncology, Johnson & Johnson, Schering-Plough, Bristol-Myers Squibb, and ChemGenex Pharmaceuticals. He is also a member of the Speaker’s Bureau for Novartis Oncology and Celgene. Dr O’Brien has received research support from Genentech BioOncol, Berlex, and Biogen Idec. Dr Rios is a member of the Speaker’s Bureau for Bristol-Myers Squibb and has received other remuneration from Novartis. Dr Giles has received research support from Novartis Oncology, Bristol-Myers Squibb, Merck, SGX Pharmaceuticals, Amgen, and Pfizer. Dr Kantarjian has received research support from Bristol-Myers Squibb, Novartis Oncology, and MGI Pharma. This article includes discussion of investigational and/or unlabeled uses of drugs, including the use of nilotinib, p210 multipeptide vaccine, nonpeptide PR1 vaccine, and a heat-shock protein–70–based vaccine in the treatment of CML.

Keywords

Cytogenetic response
Immunotherapy
Myeloid blast crisis
Myelosuppression
Stem cell transplantation
Tyrosine kinase inhibitors

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3816/CLM.2007.s.002

Cite this

@article{b2f00581512f4b7ea3b1f07686dda0a8,

title = "Management of patients with newly diagnosed chronic myeloid leukemia: Opportunities and challenges",

abstract = "Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome. This arises from a balanced translocation between chromosomes 9 and 22, creating the bcr-abl fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation, which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy. After imatinib treatment, > 90\% of patients had a complete hematologic response, and 70\%-80\% had a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging and exhibit a major change in the natural history of the disease. The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance. The outlook today for patients with CML is much brighter than that of a few years ago.",

keywords = "Cytogenetic response, Immunotherapy, Myeloid blast crisis, Myelosuppression, Stem cell transplantation, Tyrosine kinase inhibitors",

author = "Elias Jabbour and Jorge Cortes and Susan O'Brien and Rios, \{Mary Beth\} and Francis Giles and Hagop Kantarjian",

note = "Funding Information: Dr Jabbour is a member of the Speaker{\textquoteright}s Bureau for Novartis Oncology and Bristol-Myers Squibb. Dr Cortes has received research support from Breakthrough Therapeutics, Novartis Oncology, Johnson \& Johnson, Schering-Plough, Bristol-Myers Squibb, and ChemGenex Pharmaceuticals. He is also a member of the Speaker{\textquoteright}s Bureau for Novartis Oncology and Celgene. Dr O{\textquoteright}Brien has received research support from Genentech BioOncol, Berlex, and Biogen Idec. Dr Rios is a member of the Speaker{\textquoteright}s Bureau for Bristol-Myers Squibb and has received other remuneration from Novartis. Dr Giles has received research support from Novartis Oncology, Bristol-Myers Squibb, Merck, SGX Pharmaceuticals, Amgen, and Pfizer. Dr Kantarjian has received research support from Bristol-Myers Squibb, Novartis Oncology, and MGI Pharma. This article includes discussion of investigational and/or unlabeled uses of drugs, including the use of nilotinib, p210 multipeptide vaccine, nonpeptide PR1 vaccine, and a heat-shock protein–70–based vaccine in the treatment of CML.",

year = "2007",

month = mar,

doi = "10.3816/CLM.2007.s.002",

language = "English (US)",

volume = "7",

pages = "S51--S57",

journal = "Clinical Lymphoma and Myeloma",

issn = "1557-9190",

publisher = "Cancer Media Group",

number = "SUPPL. 2",

}

TY - JOUR

T1 - Management of patients with newly diagnosed chronic myeloid leukemia

T2 - Opportunities and challenges

AU - Jabbour, Elias

AU - Cortes, Jorge

AU - O'Brien, Susan

AU - Rios, Mary Beth

AU - Giles, Francis

AU - Kantarjian, Hagop

N1 - Funding Information: Dr Jabbour is a member of the Speaker’s Bureau for Novartis Oncology and Bristol-Myers Squibb. Dr Cortes has received research support from Breakthrough Therapeutics, Novartis Oncology, Johnson & Johnson, Schering-Plough, Bristol-Myers Squibb, and ChemGenex Pharmaceuticals. He is also a member of the Speaker’s Bureau for Novartis Oncology and Celgene. Dr O’Brien has received research support from Genentech BioOncol, Berlex, and Biogen Idec. Dr Rios is a member of the Speaker’s Bureau for Bristol-Myers Squibb and has received other remuneration from Novartis. Dr Giles has received research support from Novartis Oncology, Bristol-Myers Squibb, Merck, SGX Pharmaceuticals, Amgen, and Pfizer. Dr Kantarjian has received research support from Bristol-Myers Squibb, Novartis Oncology, and MGI Pharma. This article includes discussion of investigational and/or unlabeled uses of drugs, including the use of nilotinib, p210 multipeptide vaccine, nonpeptide PR1 vaccine, and a heat-shock protein–70–based vaccine in the treatment of CML.

PY - 2007/3

Y1 - 2007/3

N2 - Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome. This arises from a balanced translocation between chromosomes 9 and 22, creating the bcr-abl fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation, which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy. After imatinib treatment, > 90% of patients had a complete hematologic response, and 70%-80% had a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging and exhibit a major change in the natural history of the disease. The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance. The outlook today for patients with CML is much brighter than that of a few years ago.

AB - Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome. This arises from a balanced translocation between chromosomes 9 and 22, creating the bcr-abl fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation, which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy. After imatinib treatment, > 90% of patients had a complete hematologic response, and 70%-80% had a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging and exhibit a major change in the natural history of the disease. The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance. The outlook today for patients with CML is much brighter than that of a few years ago.

KW - Cytogenetic response

KW - Immunotherapy

KW - Myeloid blast crisis

KW - Myelosuppression

KW - Stem cell transplantation

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=34247869894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247869894&partnerID=8YFLogxK

U2 - 10.3816/CLM.2007.s.002

DO - 10.3816/CLM.2007.s.002

M3 - Article

C2 - 17382013

AN - SCOPUS:34247869894

SN - 1557-9190

VL - 7

SP - S51-S57

JO - Clinical Lymphoma and Myeloma

JF - Clinical Lymphoma and Myeloma

IS - SUPPL. 2

ER -

Management of patients with newly diagnosed chronic myeloid leukemia: Opportunities and challenges

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this